EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Prodia Widyahusada Tbk PT (PRDA) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Prodia Widyahusada Tbk PT IDR 4,195, price IDR 2,860, upside +46.7%, quality 74 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · ID · ISIN ID1000138001

PW Thin data Sep 24, 2026

Prodia Widyahusada Tbk PT

PRDA · JK

UndervaluedThe stock appears undervalued with acceptable quality.

✓Fair value 4,195 IDR · Undervalued (+47%)
✓Quality 74/100
!Mixed Growth (revenue 5y +4.0 %/yr)
!Thin margins · 9.4% net margin (TTM)
✓Low debt · generates free cash flow
✓Ranks above peers (12/14)
!Narrow moat 44/100
!Insider activity 45/100
!Evidence only low, so the estimate is less certain
!Weak on future: 19 out of 100

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

7,229 IDR 2,122 IDR Fair Value 4,195 IDR Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 2,122 IDR – 7,229 IDR · fair‑value band 3,361 IDR – 5,454 IDR · the 2,860 IDR price screens below the 4,195 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Prodia Widyahusada Tbk PT in your weekly email

Every Wednesday you see whether Prodia Widyahusada Tbk PT is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PT Prodia Widyahusada Tbk provides clinical laboratory services in Indonesia. The company offers test services, such as genomic, laboratory, and non-laboratory tests, as well as test panels; doctor consultation and teleconsultation services; vaccines; home services; and research support services.

Show more

PT Prodia Widyahusada Tbk provides clinical laboratory services in Indonesia. The company offers test services, such as genomic, laboratory, and non-laboratory tests, as well as test panels; doctor consultation and teleconsultation services; vaccines; home services; and research support services. It also engages in the operation of Prodia Health Care, a personalized medicine-based wellness clinic; and specialty clinics, including Prodia Children, Prodia Women, and Prodia Senior. The company was founded in 1973 and is headquartered in Jakarta Pusat, Indonesia. PT Prodia Widyahusada Tbk operates as a subsidiary of PT Prodia Utama.

Stock analysis

Prodia Widyahusada Tbk PT (PRDA) currently trades at 2,860 IDR, while our model-based Fair Value estimate is 4,195 IDR, implying the stock looks roughly 31.8% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 5,055 IDR per share, and 18 of the 25 models we run sit above the 2,860 IDR price.

Bear case: the Dividend Discount group reads lowest at 1,748 IDR, and 7 of the 25 models stay below the price. Evidence for this calculation is low.

Scenario range: 3,361 IDR (bear) to 5,454 IDR (bull), the price of 2,860 IDR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Prodia Widyahusada Tbk PT reported revenue of 2.3T IDR in FY2025 versus 2.7T IDR in FY2021, a compound −3.7%/yr. Reported net income was 207B IDR in FY2025, compounding −24.1%/yr from FY2021.

Key figures

Market cap 2.6T IDR (≈ $260M) · P/E ratio 12.0 · P/S ratio 1.08 · EPS (TTM) 239.24 IDR · Dividend yield 7.6% · Net margin 9.1% · Return on equity 8.8% · Return on assets (EBIT) 15.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 33% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 47%, PRDA screens cheaper than that median.

Fair Value models

Bear 3,361 IDR Fair Value 4,195 IDR Bull 5,454 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (175.01 IDR per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 3,854 IDR 4,859 IDR 6,035 IDR 82
Growth DCF 3,885 IDR 4,784 IDR 5,787 IDR 80
Owner Earnings 4,132 IDR 5,224 IDR 6,502 IDR 78
All 25 models by family
DCF Models
FCF DCF 3,854 IDR 4,859 IDR 6,035 IDR 82
Owner Earnings 4,132 IDR 5,224 IDR 6,502 IDR 78
5Y Revenue Exit 3,291 IDR 4,362 IDR 5,658 IDR 74
5Y EBITDA Exit 4,791 IDR 7,049 IDR 9,578 IDR 75
5Y P/E Exit 3,937 IDR 5,520 IDR 7,095 IDR 72
10Y Revenue Exit 3,468 IDR 4,384 IDR 5,484 IDR 68
10Y EBITDA Exit 4,323 IDR 5,942 IDR 7,939 IDR 69
10Y P/E Exit 3,865 IDR 5,055 IDR 6,384 IDR 65
Earnings-Based
Graham-Dodd 1,580 IDR 3,913 IDR 5,071 IDR 65
PEG = 1.0 709.30 IDR 1,013 IDR 1,317 IDR 57
EPV 2,021 IDR 2,184 IDR 2,316 IDR 74
Dividend Discount
Gordon GGM 1,269 IDR 1,972 IDR 2,626 IDR 68
DDM Multi-Stage 1,269 IDR 1,748 IDR 2,168 IDR 67
Multiples
P/E Multiple 3,835 IDR 5,113 IDR 6,391 IDR 63
P/S Multiple 2,963 IDR 3,951 IDR 4,939 IDR 58
P/B Multiple 2,963 IDR 3,951 IDR 4,939 IDR 55
EV/EBIT 3,915 IDR 4,999 IDR 6,084 IDR 66
EV/EBITDA 6,273 IDR 8,144 IDR 10,015 IDR 67
EV/Revenue 2,983 IDR 3,978 IDR 4,974 IDR 54
Asset-Based
NCAV (Graham) 1,344 IDR 1,801 IDR 2,688 IDR 54
Growth DCF
Growth DCF 3,885 IDR 4,784 IDR 5,787 IDR 80
Rev-Margin DCF 3,291 IDR 4,418 IDR 5,657 IDR 74
Economic Profit
Residual Income 2,080 IDR 2,193 IDR 2,273 IDR 76
ROIC Compounder 2,021 IDR 2,184 IDR 2,316 IDR 72
Growth Earnings
Growth-Adj P/E 2,937 IDR 4,195 IDR 5,454 IDR 67

Open the full fair value analysis →

Notify me when PRDA reaches fair value

Put PRDA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 74/100

Of which business quality 75 · Market factors (momentum, volatility) 68

Profitability 55
Margins and returns on capital today
Quality Growth 32
Are margins and returns improving?
Cashflow 79
Earnings quality: real cash, not paper profit
Fin. Strength 95
Balance sheet, leverage, solvency risk
Investment 95
Disciplined investing over empire-building
Low Volatility 78
Calm price path (market factor)
Momentum 58
Price trend over the last 3–12 months (market factor)
52W Momentum 74
Distance to the 52-week high (market factor)
Net Issuance 97
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 66/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
Start year 2020 (pandemic). Over 10 years: +6.7% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+3.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−4.5%
Dividend (yield on the price)7.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−5% vs 14%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 10%
Start year 2020 (pandemic)

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−6.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about −8.7% a year for the price.

Watch PRDA, get fair value alerts →

Compare Prodia Widyahusada Tbk PT with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 141 stocks

Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 74 · Top 25%
Fair Value upside +47% · Top 25%
Profitability
Return on equity (TTM) 9% · Above median
Return on assets 6% · Top 25%
Net margin (TTM) 9% · Above median
Operating margin (TTM) 4% · Below median
Growth and dividend
Revenue growth 4% · Below median
Dividend yield (TTM) 7.6% · Top 25%
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (TTM) 12.0× · Cheapest 25%
P/B 1.09× · Cheaper than median
P/S (TTM) 1.13× · Cheaper than median
P/FCF 0.0× · Cheapest 25%
EV/EBITDA 5.8× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)96 · sector 0
FUTURE (revenue growth)19 · sector 25
PAST (return on equity)35 · sector 9
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)100 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $658.52 $682.58 +4%
Danaher Corporation DHR $221.09 $207.76 −6%
WuXi AppTec Co 2359 HK$207.60 HK$228.36 +10%
Lonza Group LONN CHF 562.80 CHF 151.69 −73%
IDEXX Laboratories, Inc IDXX $521.50 $495.84 −5%
Agilent Technologies, Inc A $167.26 $63.90 −62%
Waters Corporation WAT $425.74 $106.31 −75%
IQVIA Holdings IQV $270.09 $295.80 +10%
Illumina, Inc ILMN $247.46 $272.21 +10%
Mettler-Toledo International Inc MTD $1,491 $635.75 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Prodia Widyahusada Tbk PT Fair Value". https://www.fairvalue-calculator.com/stock/PRDA

Frequently asked questions

Is Prodia Widyahusada Tbk PT (PRDA) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 4,195 IDR versus a price of 2,860 IDR, about +47% upside (undervalued).
What is the fair value of PRDA?
Our model-based fair value for Prodia Widyahusada Tbk PT is 4,195 IDR (as of Sep 24, 2026), built from audited fundamentals. The current price: 2,860 IDR.
What is the quality score of PRDA?
Prodia Widyahusada Tbk PT has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Prodia Widyahusada Tbk PT (PRDA)?
Our model-based price target is the fair value of 4,195 IDR (as of Sep 24, 2026) from 25 valuation models. Cautious scenario 3,361 IDR, optimistic scenario 5,454 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Prodia Widyahusada Tbk PT stock forecast for 2026?
Our models put fair value at 4,195 IDR, about +47% upside versus a price of 2,860 IDR (undervalued). Cautious scenario 3,361 IDR, optimistic scenario 5,454 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Prodia Widyahusada Tbk PT (PRDA)?
Prodia Widyahusada Tbk PT reported trailing-twelve-month revenue of about 2.3T IDR (latest available figure, as of Sep 24, 2026).
Does Prodia Widyahusada Tbk PT pay a dividend?
Prodia Widyahusada Tbk PT currently shows a dividend yield of about 7.62% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Prodia Widyahusada Tbk PT (PRDA)?
For today's price to be fair in a discounted-cash-flow model, Prodia Widyahusada Tbk PT would have to grow free cash flow by -6.3 % per year for five years (discount rate 15.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.0 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of PRDA use?
Our models discount Prodia Widyahusada Tbk PT at 15.0 %: a base by market capitalisation (micro), country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Prodia Widyahusada Tbk PT that is -6.3 % per year a year over ten years, using the same discount rate (15.0 %) and the same formula as our fair value.
How much growth has Prodia Widyahusada Tbk PT (PRDA) delivered so far?
Over the past 5 years revenue at Prodia Widyahusada Tbk PT grew +4.0 % a year. The price currently implies -6.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Prodia Widyahusada Tbk PT (PRDA) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Prodia Widyahusada Tbk PT (-6.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Prodia Widyahusada Tbk PT (PRDA)?
The free-cash-flow yield on the price is 13.51 %: that much free cash flow Prodia Widyahusada Tbk PT produces per unit of market value. When it exceeds the discount rate of our models (15.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Prodia Widyahusada Tbk PT (PRDA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Prodia Widyahusada Tbk PT it is 4,195 IDR per share (as of Sep 24, 2026), against a price of 2,860 IDR. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Prodia Widyahusada Tbk PT stock overvalued or undervalued in 2026?
As of Sep 24, 2026, PRDA trades below its calculated fair value: price 2,860 IDR, fair value 4,195 IDR, a gap of about +47% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PRDA?
No. The price is what the market pays today (2,860 IDR); the fair value is what the company's own numbers justify (4,195 IDR). For Prodia Widyahusada Tbk PT the two are 1,335 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Prodia Widyahusada Tbk PT worth?
The market values Prodia Widyahusada Tbk PT at about 2.6T IDR (market capitalisation, as of Sep 24, 2026). Per share that is 2,860 IDR; our models calculate a fair value of 4,195 IDR per share.
What do the bullish and bearish scenarios say about PRDA?
Our models span a range for Prodia Widyahusada Tbk PT: cautious scenario 3,361 IDR, base 4,195 IDR, optimistic 5,454 IDR per share (as of Sep 24, 2026, price 2,860 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PRDA?
Prodia Widyahusada Tbk PT trades at a price-to-earnings ratio of 12.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 4,195 IDR is built from several models across several years. Other multiples: P/B 1.1, P/S 1.1, EV/EBITDA 5.8.
How solid is the balance sheet of Prodia Widyahusada Tbk PT (PRDA)?
Balance-sheet figures for Prodia Widyahusada Tbk PT (as of Sep 24, 2026): return on equity 8.8%, debt of 0.00 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is PRDA from its 52-week high?
Prodia Widyahusada Tbk PT trades at 2,860 IDR, at its 52-week high of 2,860 IDR and 33% above the low of 2,156 IDR (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 4,195 IDR is for.
Which stocks are comparable to Prodia Widyahusada Tbk PT?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Prodia Widyahusada Tbk PT stock attractive at the current price?
The data as of Sep 24, 2026: price 2,860 IDR, calculated fair value 4,195 IDR (+47%), Quality Score 74/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PRDA calculated?
We run Prodia Widyahusada Tbk PT through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4,195 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Prodia Widyahusada Tbk PT currently trades 47 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Prodia Widyahusada Tbk PT (PRDA)?
The closing price on Sep 23, 2026 was 2,860 IDR. Our model-based fair value is 4,195 IDR, about +47% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Prodia Widyahusada Tbk PT right now?
The rarer combination: high quality (74/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (3,361 IDR). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Where does the earnings growth of Prodia Widyahusada Tbk PT (PRDA) come from?
Earnings per share at Prodia Widyahusada Tbk PT grew +14.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.4 %, EBIT margin +4.0 %, tax rate +0.5 %, residual (interest, one-offs) +2.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Prodia Widyahusada Tbk PT

How large is the market capitalisation of Prodia Widyahusada Tbk PT (PRDA)?
The market capitalisation of Prodia Widyahusada Tbk PT is 2.6T IDR (≈ $260M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Prodia Widyahusada Tbk PT (PRDA)?
The price-to-sales ratio of Prodia Widyahusada Tbk PT is 1.08 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Prodia Widyahusada Tbk PT (PRDA)?
Earnings per share at Prodia Widyahusada Tbk PT are 239.24 IDR (price ÷ EPS = P/E 12.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Prodia Widyahusada Tbk PT (PRDA)?
The dividend yield of Prodia Widyahusada Tbk PT is 7.6% (payout 91.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Prodia Widyahusada Tbk PT (PRDA)?
The net margin of Prodia Widyahusada Tbk PT is 9.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Prodia Widyahusada Tbk PT (PRDA)?
The return on equity (ROE) of Prodia Widyahusada Tbk PT is 8.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Prodia Widyahusada Tbk PT (PRDA)?
On an EBIT basis the return on assets of Prodia Widyahusada Tbk PT is 15.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Prodia Widyahusada Tbk PT (PRDA)?
The operating margin of Prodia Widyahusada Tbk PT is 3.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Prodia Widyahusada Tbk PT (PRDA)?
Revenue at Prodia Widyahusada Tbk PT is growing +3.8% versus a year earlier (3y avg +1.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Prodia Widyahusada Tbk PT (PRDA)?
Earnings per share at Prodia Widyahusada Tbk PT are growing +163% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Prodia Widyahusada Tbk PT (PRDA) hold?
Prodia Widyahusada Tbk PT holds more cash than debt, 568B IDR net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Prodia Widyahusada Tbk PT in the live analysis

One click puts Prodia Widyahusada Tbk PT on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.